Drug treatments and interactions, disease progression and quality of life in ALS patients

References

• van Es MA, Hardiman O, Chiò A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084–98.
   PubMed Web of Science ®Google Scholar
• Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;2012:CD001447.
   PubMedGoogle Scholar
• Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
   PubMed Web of Science ®Google Scholar
• Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017;1:CD011776.
   PubMed Web of Science ®Google Scholar
• EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force . Eur J Neurol. 2012;19:360–75.
   PubMed Web of Science ®Google Scholar
• Kurt A, Nijboer F, Matuz T, Kübler A. Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs. 2007;21:279–91.
   PubMed Web of Science ®Google Scholar
• Banfi P, Ticozzi N, Lax A, Guidugli GA, Nicolini A, Silani V. A review of options for treating sialorrhea in amyotrophic lateral sclerosis. Respir Care. 2015;60:446–54.
   PubMed Web of Science ®Google Scholar
• Hobson EV, McDermott CJ. Supportive and symptomatic management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2016;12:526–38.
   PubMed Web of Science ®Google Scholar
• Karam CY, Paganoni S, Joyce N, Carter GT, Bedlack R. Palliative care issues in amyotrophic lateral sclerosis: an evidenced-based review. Am J Hosp Palliat Care. 2016;33:84–92.
   PubMed Web of Science ®Google Scholar
• Beghi E, Italian ALS Study Group, Pupillo E, Bonito V, Buzzi P, Caponnetto C, Chiò A, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:397–405.
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Joyce N, Carter GT, Paganoni S, Karam C. Complementary and alternative therapies in amyotrophic lateral sclerosis. Neurol Clin. 2015;33:909–36.
   PubMed Web of Science ®Google Scholar
• Körner S, Kollewe K, Ilsemann J, Müller-Heine A, Dengler R, Krampfl K, et al. Prevalence and prognostic impact of comorbidities in amyotrophic lateral sclerosis. Eur J Neurol. 2013;20:647–54.
   PubMed Web of Science ®Google Scholar
• Logroscino G, EURALS, Traynor BJ, O. Hardiman O, Chio' A, Couratier P, Mitchell JD, et al. Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues. J Neurol Neurosurg Psychiatry. 2008;79:6–11.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol. 1999;246(Suppl 3): III16–21.
   PubMed Web of Science ®Google Scholar
• Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46:72–83.
   PubMed Web of Science ®Google Scholar
• Ghibelli S, Marengoni A, Djade CD, Nobili A, Tettamanti M, Franchi C, et al. Prevention of inappropriate prescribing in hospitalized older patients using a computerized prescription support system (INTERcheck). Drugs Aging. 2013;30:821–8.
   PubMed Web of Science ®Google Scholar
• Pasina L, Marengoni A, Ghibelli S, Suardi F, Djade CD, Nobili A, et al. A Multicomponent intervention to optimize psychotropic drug prescription in elderly nursing home residents: an Italian Multicenter, Prospective Pilot Study. Drugs Aging. 2016;33:143–9.
   PubMed Web of Science ®Google Scholar
• Antoniazzi S, Chiarelli MT, Nobili A, Pasina L, Venturini F. The value of software that provides clinically relevant information on drug interactions. Eur J Intern Med. 2015;26:e52–3.
   PubMed Web of Science ®Google Scholar
• Grande G, Morin L, Vetrano DL, Fastbom J, Johnell K. Drug use in older adults with amyotrophic lateral sclerosis near the end of life. Drugs Aging. 2017;34:529–33.
   PubMed Web of Science ®Google Scholar
• Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monzani F. Potential drug–drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457–66.
   PubMed Web of Science ®Google Scholar
• Nam MH, Park M, Park H, Kim Y, Yoon S, Sawant VS, et al. ACS indole-substituted benzothiazoles and benzoxazoles as selective and reversible MAO-B inhibitors for treatment of Parkinson's disease. ACS Chem Neurosci. 2017;8:1519–29.
   PubMed Web of Science ®Google Scholar
• Lefaucheur R, Le Goff F, Gaillon G, Triquenot-Bagan A, Maltête D. Severe dizziness following rivaroxaban introduction in a Parkinsonian patient: drug–drug interaction? Presse Med. 2015;44:1203–4.
   PubMed Web of Science ®Google Scholar
• Buck K, Voehringer P, Ferger B. The alpha(2) adrenoceptor antagonist idazoxan alleviates l-DOP A-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J Neurochem. 2010;112:444–52.
   PubMed Web of Science ®Google Scholar
• Cacabelos R. Pharmacogenomics of Alzheimer's and Parkinson's diseases. Neurosci Lett. 2020;726:133807.
   PubMed Web of Science ®Google Scholar